Recombinant Human IL-6Rα

IL-6 is a pleotropic 26 kD protein that can act as both a pro-inflammatory cytokine and an anti-inflammatory myokine, a form of cytokine produced in muscle cells that participates in tissue regeneration and repair, maintenance of healthy bodily functioning, and homeostasis within the immune system. IL-6 plays a part in the immune, endocrine, nervous, and hematopoietic systems, in addition to bone metabolism, regulation of blood pressure and inflammation. Osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. Furthermore, IL-6 is an important mediator of fever and of the acute phase response which is the body's rapid attempt to restore homeostasis after tissue injury, infection, neoplastic growth, or immunological disturbance. In addition, IL-6 can be released into circulation in response to various stimuli including PAMPs (pathogen-associated molecular patterns) and cortisol, a hormone produced by the human body under psychologically stressful conditions. In its role as an anti-inflammatory myokine, IL-6 precedes the appearance of other cytokines in the circulation, is notably elevated with exercise, and is mediated by both its inhibitory effects on TNF-α and IL-1, and activation of IL-1ra and IL-10. IL-6 signals through a cell-surface type I cytokine receptor complex formed by the binding of IL-6 to IL-6R, forming a binary complex, which in turn combines with GP130 to transduce extracellular signaling by the activation STAT3. Hence, it is thought that blocking the interaction between IL-6 and GP130 may have therapeutic potential via the inhibition of the IL-6/GP130/STAT3 signaling pathway. Moreover, IL-6 initiates the inflammatory and auto-immune processes in many diseases such as diabetes, atherosclerosis, depression, Alzheimer's disease, rheumatoid arthritis, cancer, and various others. Thus, there is an interest in the therapeutic potential of anti-IL-6 mAbs.

The biological activity of Human Soluble Interleukin-6 Receptor α is determined by its ability to intensify the IL-6 induced growth inhibition of mouse M1 cells. The expected ED₅₀ for this effect is 5-15 ng/ml.

l aprrcpaqev argvltslpg dsvtltcpgv epednatvhw vlrkpaagsh psrwagmgrr lllrsvqlhd sgnyscyrag rpagtvhllv dvppeepqls cfrksplsnv vcewgprstp slttkavllv rkfqnspaed fqepcqysqe sqkfscqlav pegdssfyiv smcvassvgs kfsktqtfqg cgilqpdppa nitvtavarn prwlsvtwqd phswnssfyr lrfelryrae rsktfttwmv kdlqhhcvih dawsglrhvv qlraqeefgq gewsewspea mgtpwtesrs ppaenevstp mqalttnkdd dnilfrdsan atslpvqd

Leu20

Lyophilized

The predicted molecular weight of Recombinant Human sIL-6R Alpha is Mr 38 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 45-50 kDa.

38

This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Yamasaki, K. et al. (1988) Science 241:825
2. Klein, C. et al. (2005) J. Clin. Invest. 115:860
3. Mule, JJ. et al. (1992) Res. Immunol. 143:777
4. Distel, E. et al. (2009) Arth. Rheu. 60:3374